# The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.

> **NCT01365637** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 30 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** PF-05089771
- **DRUG:** PF-05089771
- **DRUG:** PF-05089771
- **DRUG:** PF-05089771

## Key facts

- **NCT ID:** NCT01365637
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2011-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01365637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01365637, "The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01365637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*